

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

B1

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07H 21/04, C12N 5/00, 5/08, 5/10, 1/21, 1/15, 15/00, 15/09, 15/12, 15/63, C07K 14/00, 14/435, 14/47, 14/705, 14/74	A1	(11) International Publication Number: WO 96/10577 (43) International Publication Date: 11 April 1996 (11.04.96)
(21) International Application Number: PCT/US95/12117 (22) International Filing Date: 21 September 1995 (21.09.95) (30) Priority Data: 08/316,231 30 September 1994 (30.09.94) US (60) Parent Application or Grant (63) Related by Continuation US 08/316,231 (CIP) Filed on 30 September 1994 (30.09.94) (71) Applicant (for all designated States except US): LUDWIG INSTITUTE FOR CANCER RESEARCH [CH/US]; 1345 Avenue of the Americas, New York, NY 10105 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): COULIE, Pierre [BE/BE]; Avenue Hippocrate 74, UCL 7459, B-1200 Brussels (BE). IKEDA, Hideyuki [JP/BE]; Avenue Hippocrate 74, UCL 7459, B-1200 Brussels (BE). BOON-FALLEUR, Thierry [BE/BE]; Avenue Hippocrate 74, UCL 7459, B-1200 Brus- sels (BE).		(74) Agent: HANSON, Norman, D.; Felfe & Lynch, 805 Third Avenue, New York, NY 10021 (US). (81) Designated States: AU, CA, CN, FI, JP, NO, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: ISOLATED NUCLEIC ACID MOLECULE CODING FOR TUMOR REJECTION ANTIGEN PRECURSOR DAGE AND USES THEREOF (57) Abstract A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as DAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as GAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigens, and their precursor molecules are described.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CN	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**ISOLATED NUCLEIC ACID MOLECULE CODING FOR TUMOR REJECTION
ANTIGEN PRECURSOR DAGE AND USES THEREOF**

**Felfe & Lynch
805 Third Avenue
New Y rk, N w Y rk 10022**

RELATED APPLICATIONS

This application is a continuation in part of application Serial Number 08/316,231, filed September 30, 1994, the disclosure of which is incorporated by reference.

FIELD OF THE INVENTION

This invention relates to a nucleic acid molecule which code for a tumor rejection antigen precursor. More particularly, the invention concerns genes, whose tumor rejection antigen precursor is processed, inter alia, into at least one tumor rejection antigen that is presented by HLA-A24 molecules. The tumor rejection antigen precursor, or "TRAP" may be processed into additional peptides presented by other MHC molecules, such as HLA-A1 and its alleles, HLA-A2, HLA-Cw*1601, HLA-B44, and so forth. The genes in question do not appear to be related to other known tumor rejection antigen precursor coding sequences, are expressed on a variety of tumors and, with the exception of testis, ovary and endometrial cells, are not expressed by normal cells.

BACKGROUND AND PRIOR ART

The process by which the mammalian immune system recognizes and reacts to foreign or alien materials is a complex one. An important facet of the system is the T lymphocyte, or "T cell" response. This response requires that T cells recognize and interact with complexes of cell surface molecules, referred to as human leukocyte antigens ("HLA"), or major histocompatibility

complexes ("MHCs"), and peptides. The peptides are derived from larger molecules which are processed by the cells which also present the HLA/MHC molecule. See in this regard Male et al., Advanced Immunology (J.P. Lipincott Company, 1987), especially chapters 6-10. The interaction of T cells and HLA/peptide complexes is restricted, requiring a T cell specific for a particular combination of an HLA molecule and a peptide. If a specific T cell is not present, there is no T cell response even if its partner complex is present. Similarly, there is no response if the specific complex is absent, but the T cell is present. This mechanism is involved in the immune system's response to foreign materials, in autoimmune pathologies, and in responses to cellular abnormalities. Much work has focused on the mechanisms by which proteins are processed into the HLA binding peptides. See, in this regard, Barinaga, Science 257: 880 (1992); Fremont et al., Science 257: 919 (1992); Matsumura et al., Science 257: 927 (1992); Latrin et al., Science 257: 964 (1992).

The mechanism by which T cells recognize cellular abnormalities has also been implicated in cancer. For example, in PCT application PCT/US92/04354, filed May 22, 1992, published on November 26, 1992, and incorporated by reference, a family of genes is disclosed, which are processed into peptides which, in turn, are expressed on cell surfaces, which can lead to lysis of the tumor cells by specific CTLs cytolytic T lymphocytes, or "CTLs" hereafter. The genes are said to code for "tumor rejection antigens precursors" or "TRAP" molecules, and the peptides derived therefrom

are referred to as "tumor rejection antigens" or "TRAs". See Traversari et al., Immunogenetics 35: 145 (1992); van der Bruggen et al., Science 254: 1643 (1991), for further information on this family of genes. Also, see U.S. patent application Serial Number 807,043, filed December 12, 1991, now U.S. Patent No. 5,342,774, incorporated by reference in its entirety. The "MAGE" family of tumor rejection antigen precursors is disclosed in this patent.

In U.S. patent application Serial Number 938,334, now U.S. Patent No. 5,405,940 the disclosure of which is incorporated by reference, it is explained that the MAGE-1 gene codes for a tumor rejection antigen precursor which is processed to nonapeptides which are presented by the HLA-A1 molecule. The nonapeptides which bind to HLA-A1 follow a "rule" for binding in that a motif is satisfied. In this regard, see e.g. PCT/US93/07421; Falk et al., Nature 351: 290-296 (1991); Engelhard, Ann Rev. Immunol. 12: 181-207 (1994); Ruppert et al., Cell 74: 929-937 (1993); Rötzschke et al., Nature 348: 252-254 (1990); Bjorkman et al., Nature 329: 512-518 (1987); Traversari et al., J. Exp. Med. 176: 1453-1457 (1992). The reference teaches that given the known specificity of particular peptides for particular HLA molecules, one should expect a particular peptide to bind to one HLA molecule, but not to others. This is important, because different individuals possess different HLA phenotypes. As a result, while identification of a particular peptide as being a partner for a specific HLA molecule has diagnostic and therapeutic ramifications, these are only relevant for individuals with that particular HLA phenotype. There

is a need for further work in the area, because cellular abnormalities are not restricted to one particular HLA phenotyp , and targeted therapy requires some knowledge of the phenotype of the abnormal cells at issue.

5 In U.S. Patent Application Serial Number 008,446, fil d January 22, 1993 and incorporated by reference, the fact that th MAGE-1 expression product is processed to a second TRA is disclosed. This second TRA is presented by HLA-Cw*1601 molecul s. The disclosure shows that a given TRAP can yield a plurality f
10 TRAs, each of which will satisfy a motif rule for binding to an MHC molecule.

 In U.S. Patent Application Serial Number 994,928, fil d December 22, 1992, and incorporated by reference herein teach s that tyrosinase, a molecule which is produced by some normal cells
15 (e.g., melanocytes), is processed in tumor cells to yield peptid s presented by HLA-A2 molecules.

 In U.S. patent application Serial No. 08/032,978, filed March 18, 1993, and incorporated by reference in its entirety, a second TRA, not derived from tyrosinase is taught to be presented by HLA-
20 A2 molecules. The TRA is derived from a TRAP, but is coded for by a non-MAGE gene. This disclosure shows that a particular HLA molecule may present TRAs derived from different sources.

 In U.S. patent application Serial No.08/079,110, filed June 17, 1993 and incorporated by reference herein, an unrelated tum r rejection antig n pr cursor, the s -call d "BAGE" precursor is
25 described. Th BAGE precursor is n t r lated to the MAGE family.

In U.S. patent applications Serial No. 08/096,039 and Serial No. 08/250,162, both of which are incorporated by reference, an unrelated TRAP precursor GAGE is also disclosed.

The work which is presented by the papers, patent, and patent applications cited supra deals, in large part, with the MAGE family of genes, and the unrelated BAGE and GAGE genes. It has now been found, however, that additional tumor rejection antigen precursors are expressed by cells. These tumor rejection antigen precursors are referred to as "DAGE" tumor rejection antigen precursors. They do not show homology to the MAGE family of genes, the BAGE gene, or the GAGE gene. Thus the present invention relates to genes encoding such TRAPs, the tumor rejection antigen precursors themselves as well as applications of both.

What further characterizes the DAGE tumor rejection antigen precursors is that their expression by tumor cells is much more widespread than the other tumor rejection antigen precursors described previously. This is proven infra. Yet, the expression of the family by normal cells is again limited to testis, ovary and endometrial cells. Thus, a much more general means of assaying for the presence of transformed cells is available than previously. This will be seen by way of the examples.

The invention is elaborated upon further in the disclosure which follows.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 describes, collectively, ⁵¹Cr release, cell lysis studies. In particular:

Figure 1A shows lysis of cell line LB33-MEL.B-1;

5 Figure 1B shows lysis of LB33 B cells transformed by EBV. These are autologous cells.

Figure 1C shows lysis studies on NK target K562. In each case, the effector cells were CTL clone LB33-CTL-269/17.

10 Figure 2 presents studies on the inhibition of lysis by cytolytic T cells in the presence of an anti-HLA-A24 monoclonal antibody. The studies were carried out in the presence or absence of 30 fold dilutions of culture medium of a hybridoma producing the HLA-A24 specific monoclonal antibody.

15 Figures 3A & 3B show the result of lysis experiments following transfection of LB804-ALL cells with the sequence Hi2.

20 Figure 4 shows the results obtained in a TNF release assay using CTL 269/17. The stimulator cells were either LB33-MEL.B-1, COS-7 cells, COS-7 cells transfected with a cDNA sequence coding for HLA-A24, or COS-7 cells transfected with both cDNA sequence coding for HLA-A24, and cDNA coding for a tumor rejection antigen precursor in accordance with this invention.

Figure 5 compares induced lysis using various peptides derived from DAGE.

25 Figure 6 shows the expression of DAGE in various tissue samples.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS**Example 1**

Melanoma cell line LB33-MEL.B was derived from a metastasis of patient LB33, using standard techniques. Tumor cells were then
5 cloned by limiting dilution, resulting in clone LB33-MEL.B-1, used hereafter.

Samples containing mononuclear blood cells (which include lymphocytes) were taken from patient LB33. Samples of clone LB33-MEL.B-1 were contacted to the mononuclear blood cell samples. Th
10 mixtures were observed for lysis of the LB33-MEL.B-1 cells, this lysis indicating that cytolytic T cells ("CTLs") specific for a complex of peptide and HLA molecule presented by the cells were present in the sample.

The lysis assay employed was a chromium release assay
15 following Herin et al., Int. J. Cancer 39:390-396 (1987), the disclosure of which is incorporated by reference. The assay, however, is described herein. The target melanoma cells were grown in vitro. Prior to labelling, these cells were incubated for 48 hours, in the presence of 50 U/ml of IFN- γ to increase the
20 expression of HLA Class I molecules. The cells were then resuspended at 10^7 cells/ml in DMEM, supplemented with 10 mM HEPES and 30% FCS (i.e. fetal calf serum), and incubated for 45 minutes at 37°C with 200 μ Ci/ml of Na(51 Cr)O₄. Labelled cells were washed three times with DMEM, supplemented with 10 mM Hepes. These were

then resuspended in DMEM supplemented with 10 mM Hepes and 10% FCS, after which 100 ul aliquots containing 10^3 cells, were distributed into 96 well microplates. PBL containing samples were added in 100 ul of the same medium, and assays were carried out in duplicate. Plates were centrifuged for 4 minutes at 100g, and incubated for four hours at 37°C in a 5.5% CO₂ atmosphere.

Plates were centrifuged again, and 100 ul aliquots of supernatant were collected and counted. Percentage of ^{51}Cr release was calculated as follows:

10 $\% \text{ } ^{51}\text{Cr release} = \frac{(\text{ER}-\text{SR})}{(\text{MR}-\text{SR})} \times 100$

where ER is observed, experimental ^{51}Cr release, SR is spontaneous release measured by incubating 10^5 labeled cells in 200 μl of medium alone, and MR is maximum release, obtained by adding 100 μl 0.3% Triton X-100® to target cells.

Those mononuclear blood cell samples which showed high CTL activity were expanded and cloned via limiting dilution, and were screened again, using the same methodology.

20 The same method was used to test target K562 cells. When EBV-B cells were used, the only change was the replacement of DMEM medium by Hank's medium, supplemented with 5% FCS.

These experiments led to isolation of CTL clone LB33-CTL-269/17 from patient LB33. As figures 1A-1C indicate, this CTL clone lysed LB33-MEL.B-1 tumor cells, but not EBV transformed B cells of patient LB33, nor K562 cells. When the target cells were

incubated with a monoclonal antibody specific to HLA-A24, lysis was inhibited, suggesting that any TRA peptide involved is presented by HLA-A24. Figure 2 shows these results.

A second CTL clone, referred to as LB33-CTL-269/1, lysed LB33-MEL.B-1 but not EBV-B transformed B cells nor K562, thus suggesting that the same target antigen was recognized. Lysis by clone LB33-CTL-269/1 was also inhibited by the anti-HLA-A24 monoclonal antibody.

Example 2

Having identified the presenting MHC molecule as HLA-A24, studies were carried out to identify the coding sequence for the protein molecule, referred to hereafter as the "tumor rejection antigen precursor" or "TRAP" molecule which was the source of the presented peptide.

To do this, total RNA was isolated from cell line LB33-MEL.B-1. The mRNA was isolated using an oligo-dT binding kit, following well recognized techniques. Once the mRNA was secured, it was transcribed into cDNA, again using standard methodologies. The cDNA was then ligated to EcoRI adaptors and cloned into the EcoRI site of plasmid pCDNA-I/Amp, in accordance with manufacturer's instructions. The recombinant plasmids were then electroporated into DH5 α *E. coli* (electroporation conditions: 1 pulse at 25 μ farads, 2500 V).

The transfected bacteria were selected with ampicillin (50 μ g/ml), and then divided into 400 pools of 100 clones each. Each

pool represented about 50 different cDNAs, as analysis showed that all plasmids contained an insert and cloning was not directional. Each pool was amplified to saturation, and plasmid DNA was isolated via alkaline lysis, potassium acetate precipitation and phenol extraction, following Maniatis et al., in Molecular Cloning: A Laboratory Manual (Cold Spring Harbor, N.Y., 1982). Cesium gradient centrifugation was not used.

Example 3

The amplified plasmids were then transfected into eukaryotic cells. Samples of COS-7 cells were seeded, at 15,000 cells/well into tissue culture flat bottom microwells, in Dulbecco's modified Eagles Medium ("DMEM") supplemented with 10% fetal calf serum. The cells were incubated overnight at 37°C, medium was removed and then replaced by 30 µl/well of DMEM medium containing 10% Nu serum, 400 µg/ml DEAE-dextran, 100 µM chloroquine, 100 ng of plasmid pCDNA-I/Amp-A2A and 100 ng of DNA of a pool of the cDNA library described supra. Plasmid pCDNA-I/Amp-A24 contains the HLA-A24 gene from LB33-MEL.B which was identified as allele HLA-A*2402. Following four hours of incubation at 37°C, the medium was removed, and replaced by 50 µl of PBS containing 10% DMSO. This medium was removed after two minutes and replaced by 200 µl of DMEM supplemented with 10% of FCS.

Following this change in medium, COS cells were incubated for 48 hours at 37°C. Medium was then discarded, and 2000 cells of described CTL clone 269/1 were added, in 100 µl of Iscov's medium

containing 10% pooled human serum. Supernatant was removed after 24 hours, and TNF content was determined in an assay on WEHI cells, as described by Traversari et al., Immunogenetics 35: 145-152 (1992), the disclosure of which is incorporated by reference.

5 Of 400 pools tested, one was positive.

Example 4

The bacteria of the positive pool were subcloned. Plasmid DNA was extracted from 600 individual colonies, and cotransfected with pCDNA-I/Amp-A24 into new samples of COS cells in the same manner
10 as described supra, and the cells were again tested for stimulation of CTL 269/1. A positive clone was found, identified as "5E10".

The plasmid from the positive clone was removed, and sequenced following art known techniques.

The sequence identified is 1554 base pairs long (see SEQ ID
15 NO: 1). This sequence contains an open reading frame encoding 518 amino acids.

The 104 nucleotides at positions 1310-1413 were found to be identical to the 104 first base pairs of a 113 base pair sequence recorded in Genbank: L25344, HOMRBCESTC "Human (clone 17)"
20 erythroleukemic expressed sequence tag (EST) mRNA fragment. No sequences were found which corresponded to the sequence of SEQ ID NO: 1, however.

Example 5

Following the isolation of 5E10, described supra, it was used as a probe in a standard Northern Blot, using total RNA of LB 33-MEL, and standard techniques.

5 The results showed a band of about 2.5 kilobases, which is, of course, somewhat longer than the probe itself. This suggests that clone 5E10 is not complete.

10 As a result, the same cDNA library prepared from RNA of LB33-MEL cells was screened, again using cDNA 5E10 as a probe. A cDNA clone of 2148 base pairs was identified, and sequenced. It is referred to as Hi2. The sequence of 5E10 is completely included in that of Hi2, except that at base 254, Hi2 has cytosine, while 5E10 has thymine.

Example 6

15 Following the isolation of Hi2, a set of experiments were carried out in order to confirm that Hi2 was a tumor rejection antigen precursor encoding sequence. Specifically, HLA-A24 positive leukemia cell line LB804-ALL was used, because prior experiments had shown that CTL 269/17, described supra, did not
20 lyse this line.

Cells of the leukemia line were transfected with expression vector pEF-BOS-puro.PL3, which carries a gene conferring puromycin resistance, and into which cDNA Hi2 was cloned. Puromycin resistant populations were selected, and isolated. This provided

25

to be sensitive to CTL 269/17, thus indicating that expression of antigen LB33-E is not dependent upon the high copy number which results from COS-7 transfection.

Figures 3A and 3B show these results, where 3A shows the leukemia cell line before transfection, where CTL 269/17 is the responder.

The sequence of H12 is provided as SEQ ID NO:2. When comparing it to other sequences in data banks, it was found that nucleotides 1486-1589 are identical to 104 base pairs of a 113 base pair sequence expressed in myeloid leukemia cell line K562 (Gen Bank:L25344). Nucleotides 1983-2128 are identical to 146 of 147 base pairs expressed in promyelocytic leukemia cell line. HL-60 (DDBJ:D20455), while nucleotides 1736-2067 are 97% homologous with 325 base pairs of a 332 base pair cDNA found in cells of human testis (Gen Bank:T19428).

Analysis of the sequence of H12 shows an open reading frame encoding a putative protein of 509 amino acids, which has no signal sequence. No significant homology was found with other proteins in sequences in data banks.

Example 7

H12 was then used to isolate genomic DNA encoding the pertinent protein. The DNA of 12 groups of 70,000 cosmids of a human genomic DNA library was collected, and 5E10 was used to hybridize to these, using standard methodologies. The clones hybridized to one cosmid group. Following subcloning on a cosmid

was identified which hybridized with cDNA clone 5E10. The sequence was secured by using primers deduced from the cDNA sequence. The sequence presents six exons, with the open reading frame spanning exons 3-6.

5 Example 8

The information in SEQ ID NO: 1 was sufficient to permit analysis of gene expression via polymerase chain reaction (PCR).

The following primers were used:

10 5'-GCCTGCTGAAGGATGAGGCC-3'
(SEQ ID NO: 3)

5'-GGTGCTGCAGGAGACTCTGC-3'
(SEQ ID NO: 4)

These correspond to nucleotides 157-176, and 1328-1347 of SEQ ID NO: 1, respectively.

15 The PCR was carried out for 28 cycles, (1 cycle: 1 minute 94°C, 2 minutes at 65°C, 3 minutes at 72°C). In carrying out the PCR, 2.5 ul of cDNA template, prepared as described supra, was combined with 2.5 ul of 10x Dynazyme buffer, 0.25 ul of each dNTP (10 mM), 0.5 ul of each primer (20 mM), 0.5U Dynazyme (0.25 ul stock, 2 U/ml),
20 and 18.5 ul water. Table 1, which follows, sets forth the results. Note the expression over a number of varied tumor samples, as well as tumor cell lines, indicating that this is not an artifact of cell culture. Further, with the exception of testis, there is absolutely no expression in normal tissues.

Tabl 1

Expression of the gene corresponding to cDNA clone 5E10 in tumors and normal tissues

Normal tissues:

Liver	0/1
Stomach	0/1
Colon	0/1
Lung	0/1
Spleen	0/1
Heart	0/1
Breast	0/1
Bladder	0/1
Prostate	0/1
Thymus	0/1
Bone marrow	0/1
Blood lymphocytes	0/1
Fibroblasts	0/1
Testis	2/2

Tumor samples:

Melanoma	5/5
Lymphoma	2/5
Chronic Myeloid Leukemia	1/2
Chronic Lymphoid Leukemia	1/5
Acute Myeloid Leukemia	0/6
Renal Carcinoma	3/6
Sarcoma	2/3
Breast carcinoma	2/5

Tumor cell lines:

Melanoma	11/15
Leukemia	3/6
Burkitt lymphoma	2/4

Example 2

A second assay was carried out, based upon TNF (tumor necrosis factor) release. In this assay, COS-7 cells (10,000 cells/mirowell) were transfected with the plasmid pcDNAI/Amp carrying HLA-A24 cDNA, as described supra, or cotransfected with this plasmid and plasmid pcDNAI/Amp containing SEQ ID NO: 1, described supra. Twenty four hours after transfection, 3000 cells of CTL 269/17 were added to the transfectants. In a control, the same number of LB33-MEL.B-1 cells were used. The concentration of TNF released in the cell medium was measured after 24 hours, using TNF sensitive cell line WEHI-164c13.

The results are presented in figure 4. They show that TNF release by CTLs was provoked only with COS cells cotransfected with vectors expressing HLA-A24 and SEQ ID NO 1. COS cells do not present HLA-A24 on their own, nor do they express the sequences of the invention. When cotransfected, however, they were able to provoke TNF release to a level nearly that of autologous cell line LB33-MEL.B-1.

The results, as set forth in figure 3, not only show that the material of SEQ ID NO: 1 does in fact code for a tumor rejection antigen precursor which stimulates CTLs when processed, it also shows that, as elaborated upon infra, one can assay for the presence of CTLs which are specific for tumor cells by using non-transformed cells, such that the resulting transfectant will express both HLA-A24 and DAGE.

Example 10

As it has been well established that TRAPs are processed to smaller tumor rejection antigens, experiments were undertaken to identify a tumor rejection antigen or antigens produced from the described sequences.

The cDNA for 5E10 was partially digested with the endonuclease *NsiI*, and the thus truncated cDNA clones were cotransfected into COS-7 cells with HLA-A24 cDNA clones. Transfectants were then tested for expression of LB33-E, by adding CTL 269/17, and measuring TNF production.

Results are summarized in figure 5. Nucleotides corresponding to nucleotides 1047-1260 of the cDNA of H12 were found to encode the relevant antigen. Four sequences in this region which (i) were 9 or 10 amino acids long, (ii) had Tyr or Phe at position 2, and (iii) had one of Phe, Leu, Ile, or Trp at C-terminus were possible. This is the motif for HLA-A24 binding described by Kubo, et al, J. Immunol 152:3913 (1994); Meier, et al, Immunogenetics 40:306-308 (1994). These were synthesized, and incubated with cells of MHC class I negative B-cell lymphoblastoid line C1R, which had been transfected with the HLA-A24 cDNA clone described supra. One peptide:

Leu Tyr Val Asp Ser Leu Phe Phe Leu (SEQ ID NO. 5), was found to sensitize the transfected C1R-A24 cells to lysis by the anti LB33-E CTLs, with half maximal effect at 500 nM.

Comparative experiments were carried out, wherein peptides containing one additional N- or C-terminal amino acid, and where the C-terminal Leu was deleted, were used. SEQ ID NO:7 sensitized the cells to lysis, although to a lesser degree than SEQ ID NO:5.

5 SEQ ID NOS : 8 and 9 were much less sensitive in sensitizing the cells, as is shown in figure 6. Peptides used extended SEQ ID NO:5 at the N-terminus with Ala (SEQ ID NO:7), and by deleting the C-terminal Leu (SEQ ID NO:8). Addition of Arg to the C terminus resulted in SEQ ID NO:9. In these experiments, ⁵¹Cr labeled C1R-A24
10 cells were incubated for 30 minutes in the presence of indicated peptide concentrations. CTLs were added at E/T ratios of 10:1, and chromium release was measured after 4 hours.

Example 11

Tests were then carried out, using the well known reverse transcriptase polymerase chain reaction ("RT-PCR"), to determine
15 expression of the subject gene. In table 2, which follows the results are shown.

The higher proportion of positive tumors were melanomas (91%), lung squamous carcinomas (78%), and adenocarcinomas (46%), as well
20 as renal carcinomas (43%), sarcomas (40%), and acute leukemias (33%).

There was also some expression in normal tissues. Testis, ovary, and endometrium expressed about 10% of what was found in cell line LB33-MEL, while low levels were found in skin, brain,
25 heart, kidney, and adrenal tissue. See Table 2 and figure 6.

Tabl 2. Expressi n f gene DAGE by tumoral tissues.

Tumor samples

Brain tumors	1/7	
Colorectal carcinomas	2/51	4%
Gastric carcinomas	1/2	
Naevi	9/18	
Melanomas	43/49	88%
primary lesions	144/152	95%
metastases	5/9	
ocular	2/3	
Neuroblastomas	17/44	39%
Head and neck squamous carcinomas	1/4	
Lung carcinomas	12/26	46%
SCLC	51/65	78%
NSCLC	2/20	
adenocarcinomas	24/56	43%
squamous carcinomas	4/36	11%
Prostatic carcinomas	9/42	21%
Renal carcinomas	10/25	40%
Bladder tumors	45/169	27%
superficial	3/5	
infiltrating	21/63	33%
Sarcomas		
Mammary carcinomas		
Thyroid carcinomas		
Acute leukemias		

Tumor cell lines

Melanomas	72/74	97%
Sarcomas	4/5	
Lung carcinomas	19/27	70%
SCLC	2/2	
NSCLC	2/18	
Mesotheliomas	2/7	
Head and neck tumors	2/3	
Bladder tumors	1/15	
Colorectal carcinomas	9/12	
Renal carcinomas		
EBV-transformed lymphoblastoid B cell lines	0/8	

The foregoing examples show the isolation of a nucleic acid molecule which codes for a tumor rejection antigen precursor. This "TRAP" coding molecule, however, is not homologous with any of the previously disclosed MAGE, BAGE or GAGE coding sequences described in the references set forth supra. Hence, one aspect of the invention is an isolated nucleic acid molecule having the nucleotide sequence set forth in SEQ ID NO : 1 or SEQ ID NO : 2, as well as those portions of SEQ ID NO: 1 or SEQ ID NO:2 which express TRAs such as those encoding SEQ ID NOS : 5, 7 and 9 presented by MHC molecules such as HLA-A24, and derived from DAGE. This sequence is not a MAGE, BAGE or GAGE coding sequence, as will be seen by comparing it to the sequence of any of these genes as described in the cited references. Also a part of the invention are those nucleic acid sequences which also code for a non-MAGE, non-BAGE and non-MAGE tumor rejection antigen precursor but which hybridize to the nucleic acid molecule having the nucleotide sequence of SEQ ID NO: 1 and/or 2 under stringent conditions. The term "stringent conditions" as used herein refers to parameters with which the art is familiar. More specifically, stringent conditions, as used herein, refers to hybridization in 1M NaCl, 1% SDS, and 10% dextran sulfate. This is followed by two washes of the filter at room temperature for 5 minutes, in 2xSSC, and a wash for 30 minutes in 2xSSC, 0.1% SDS. There are other conditions, reagents, and so forth which can be used, which result in the same or higher degree of stringency. The skilled

artisan will be familiar with such conditions, and, thus, they are not given here.

The widespread distribution in the expression of this gene (7 out of 8 types of tumor were found to express it), shows that the isolated nucleic acid molecule can be used as a diagnostic probe to determine presence of transformed cells. The identification of melanoma was 100%, so on a very basic level, the isolated nucleic acid molecules may be used to determine whether or not melanoma is present. Note that there are many ways available to the skilled artisan to confirm that a tumor sample is a melanoma sample, and these need not be reiterated here. Further, the rate of success in identifying tumors is in accordance with nucleic acid based diagnostic methods for determining transformation of cells.

It will also be seen from the examples that the invention embraces the use of the sequences in expression vectors, which may be used to transform or to transfect host cells and cell lines, be these prokaryotic (e.g., *E. coli*), or eukaryotic (e.g., CHO or COS cells). The expression vectors require that the pertinent sequence, i.e., those described supra, be operably linked to a promoter. As it has been found that human leukocyte antigen HLA-A24 presents a tumor rejection antigen derived from these genes, the expression vector may also include a nucleic acid sequence coding for HLA-A24. In a situation where the vector contains both coding sequences, it can be used to transform or transfect a cell which does not normally express either one. The tumor rejection antigen precursor coding sequence may be used alone, when, e.g.,

the host cell already expresses HLA-A24. Of course, there is no limit on the particular host cell which can be used. As the vectors which contain the two coding sequences may be used in HLA-A24 presenting cells if desired, and the gene for tumor rejection antigen precursor can be used in host cells which do not express HLA-A24.

The invention also embraces so called expression kits, which allow the artisan to prepare a desired expression vector or vectors. Such expression kits include at least separate portions of each of the previously discussed coding sequences. Other components may be added, as desired, as long as the previously mentioned sequences, which are required, are included.

To distinguish the nucleic acid molecules and the TRAPs of the invention from the previously described MAGE, BAGE and GAGE materials, the invention shall be referred to as the DAGE family of genes and TRAPs. Hence, whenever "DAGE" is used herein, it refers to the tumor rejection antigen precursors coded for by the previously described sequences. "DAGE coding molecule" and similar terms, are used to describe the nucleic acid molecules themselves.

The invention as described herein has a number of uses, some of which are described herein. First, the invention permits the artisan to diagnose a disorder characterized by expression of the TRAP. These methods involve determining expression of the TRAP gene, and/or TRAs derived therefrom, such as a TRA presented by HLA-A24. In the former situation, such determinations can be carried out via any standard nucleic acid determination assay,

including the polymerase chain reaction, or assaying with labelled hybridization probes. In the latter situation, assaying with binding partners for complexes of TRA and HLA, such as antibodies, is especially preferred. An alternate method for determination is a TNF or ^{51}Cr release assay, of the types described supra.

The isolation of the TRAP gene also makes it possible to isolate the TRAP molecule itself, especially TRAP molecules containing the amino acid sequence coded for by SEQ ID NO: 2. These isolated molecules when presented as the TRA, or as complexes of TRA and HLA, such as HLA-A24, may be combined with materials such as adjuvants to produce vaccines useful in treating disorders characterized by expression of the TRAP molecule. In addition, vaccines can be prepared from cells which present the TRA/HLA complexes on their surface, such as non-proliferative cancer cells, non-proliferative transfectants, etcetera. In all cases where cells are used as a vaccine, these can be cells transfected with coding sequences for one or both of the components necessary to provide a CTL response, or be cells which express both molecules without transfection. Further, the TRAP molecule, its associated TRAs, as well as complexes of TRA and HLA, may be used to produce antibodies, using standard techniques well known to the art.

When "disorder" is used herein, it refers to any pathological condition where the tumor rejection antigen precursor is expressed. An example of such a disorder is cancer, melanoma in particular. Melanoma is well known as a cancer of pigment producing cells.

Therapeutic approaches based upon the disclosure are premised on a response by a subject's immune system, leading to lysis of TRA presenting cells, such as HLA-A24 cells. One such approach is the administration of CTLs specific to the complex to a subject with abnormal cells of the phenotype at issue. It is within the skill of the artisan to develop such CTLs in vitro. Specifically, a sample of cells, such as blood cells, are contacted to a cell presenting the complex and capable of provoking a specific CTL to proliferate. The target cell can be a transfectant, such as a COS cell of the type described supra. These transfectants present the desired complex on their surface and, when combined with a CTL of interest, stimulate its proliferation. COS cells, such as those used herein are widely available, as are other suitable host cells.

To detail the therapeutic methodology, referred to as adoptive transfer (Greenberg, J. Immunol. 136(5): 1917 (1986); Riddell et al., Science 257: 238 (7-10-92); Lynch et al., Eur. J. Immunol. 21: 1403-1410 (1991); Kast et al., Cell 59: 603-614 (11-17-89)), cells presenting the desired complex are combined with CTLs leading to proliferation of the CTLs specific thereto. The proliferated CTLs are then administered to a subject with a cellular abnormality which is characterized by certain of the abnormal cells presenting the particular complex, where the complex contains the pertinent HLA molecule. The CTLs then lyse the abnormal cells, thereby achieving the desired therapeutic goal.

The foregoing therapy assumes that at least some of the subject's abnormal cells present the relevant HLA/TRA complex.

This can be determined very easily, as the art is very familiar with methods for identifying cells which present a particular HLA molecule, as well as how to identify cells expressing DNA of the pertinent sequences, in this case a DAGE sequence. Once cells
5 presenting the relevant complex are identified via the foregoing screening methodology, they can be combined with a sample from a patient, where the sample contains CTLs. If the complex presenting cells are lysed by the mixed CTL sample, then it can be assumed that a GAGE derived, tumor rejection antigen is being presented,
10 and the subject is an appropriate candidate for the therapeutic approaches set forth supra.

Adoptive transfer is not the only form of therapy that is available in accordance with the invention. CTLs can also be provoked in vivo, using a number of approaches. One approach,
15 i.e., the use of non-proliferative cells expressing the complex, has been elaborated upon supra. The cells used in this approach may be those that normally express the complex, such as irradiated melanoma cells or cells transfected with one or both of the genes necessary for presentation of the complex. Chen et al., Proc.
20 Natl. Acad. Sci. USA 88: 110-114 (January, 1991) exemplifies this approach, showing the use of transfected cells expressing HPV E7 peptides in a therapeutic regime. Various cell types may be used. Similarly, vectors carrying one or both of the genes of interest may be used. Viral or bacterial vectors are especially preferred.
25 In these systems, the gene of interest is carried by, e.g., a Vaccinia virus or the bacteria BCG, and the materials de facto

"infect" host cells. The cells which result present the complex of interest, and are recognized by autologous CTLs, which then proliferate. A similar effect can be achieved by combining the tumor rejection antigen or the precursor itself with an adjuvant to facilitate incorporation into HLA-A24 presenting cells which then present the HLA/peptide complex of interest. The TRAP is processed to yield the peptide partner of the HLA molecule while the TRA is presented without the need for further processing.

Also a feature of this invention are isolated peptides derived from the DAGE TRAP which conform to the rules for presentation by MHC molecules. For example, in PCT application No. PCT/US93/07421, incorporated by reference herein, several motifs are described as being associated with different MHC molecules. These motifs, incorporated by reference herein, as well as those taught by, e.g. Falk et al., Nature 351: 290-296 (1991); Engelhard, Ann. Rev. Immunol 12: 181-207 (1994); Ruppert et al., Cell 74: 929-937 (1993); Rötzschke et al., Nature 348: 252-254 (1990); Bjorkman et al., Nature 329: 512-518 (1987) and Traversari et al., J. Exp. Med. 176: 1453-1457 (1992) all of which are incorporated by reference, serve as a basis for identifying appropriate peptides obtainable or derivable from the DAGE gene. These peptides may be used alone, or in mixtures, in another aspect of the invention, which is now described. Exemplary of these are the following. For HLA-A2, a binding motif is Xaa Leu Xaa Gly (Xaa)_n Leu (SEQ ID NO : 10) where n is 4 or 5. Amino acids 120-128 of SEQ ID NO : 1 correspond to this motif. A second motif for HLA-A2 replaces terminal Leu with

Val (SEQ ID NO : 3), and amino acids 375-384 satisfy this motif. For HLA-A3, the motifs are Xaa Leu (Xaa)₆ (Lys or Tyr) (SEQ ID NO : 11 and SEQ ID NO : 12). Amino acids 48-56, 100-108, 138-146, 214-222, and 257-265 of SEQ ID NO : 1 well satisfy this motif. For HLA-A11, the motif (Xaa)₇ Lys Lys (SEQ ID NO : 13) is known, and amino acids 169-178, 214-223, and 223-232 will satisfy it. For HLA-A24, the known motif is Xaa Tyr (Xaa)₆ Leu, (SEQ ID NO : 13) and is satisfied by amino acids 274-282, and 467-475 as well as SEQ ID NO : 5. For HLA-B7, the motif is Xaa Pro Arg (Xaa)₅ Leu, (SEQ ID NO : 14) and amino acids 68-76 meet it. For HLA-B8, (Xaa)₂ Lys Xaa Lys (Xaa)₃ Leu (SEQ ID NO : 15) is the motif, satisfied by amino acids 176-184 and 218-226. For HLA-B44, motif Xaa Glu (Xaa)₃ Asp (Xaa)₂ Phe (SEQ ID NO : 16) is satisfied by amino acids 204-212. For HLA-Cw*1601 is satisfied by amino acids 60-68, and 395-403.

The fact that a number of sequences are present which correspond to HLA motifs suggests what will be referred to herein as "cocktail" therapeutic and diagnostic uses. It is expected that in a typical CTL response to tumor cells, CTLs specific to more than one complex of peptide and HLA molecule will proliferate. For example, it may be the case that for HLA-A24 presenting cells, CTLs specific for HLA-A24 and amino acid sequence 467-475 will proliferate. Thus, one can optimize the assay by using both peptides when attempting to identify CTLs. Similarly, the therapeutic methods might be optimized by using more than one HLA-A24 binding peptide.

It is well known that individuals are not "monovalent" for HLA molecules, as cells present more than one kind of HLA. Thus, n can maximize diagnostic and/or therapeutic by combining a number of peptides as described supra in a diagnostic assay to determine
5 CTLs, or to treat patients in the therapies described supra.

Any concern as to false positives, is believed to be misplaced because, as noted supra, the nucleic acid molecules of the invention have been found to be expressed only in tumor cells, s the presence of CTLs to the HLA and the peptides must be considered
10 de facto evidence of the presence, at some time in the past of the present existence of a cancerous or transformed condition. Thus, cocktails of the peptides of the invention can be prepared. Determination of the components of the mixture is not difficult, because all that is needed is one or more of the HLA types
15 presented by the individual under consideration. HLA typing is a very standard technique, well known in the art; and well within the abilities and skill of the artisan.

It has been fairly well established that the blood of individuals afflicted with tumors frequently contains cytolytic T
20 cells ("CTLs") against complexes of MHC molecules and presented peptides. See, e.g., Robbins et al., Canc. Res. 54: 3124-3126 (1994); Topollian et al., J. Immunol. 142: 3714-3725 (1989); Couli et al., Int. J. Cancer 50: 289-297 (1992), all of which are incorporated by reference. Also, note Kawakami et al., J. Exp.
25 Med. 180: 347-352 (1994); Hom et al., J. Immunother 10: 153-164 (1991), Darrow et al., J. Immunol. 142(9): 3329-3335 (1989); Slovin

t al., J. Immunol. 137(9): 3042-3048 (1986), all of which are incorporated by reference. These papers all establish the usefulness of a CTL proliferation assay to diagnose cancer. Expressed generally, one takes a peripheral blood lymphocyte (PBL) containing sample from a subject to be tested. Assuming that the patient does have a tumor, or the subject's cells have begun to undergo transformation, CTLs which are specific to transformed cells will be contained in that sample. These CTLs can be stimulated to proliferate via contact with a target cell which presents complexes of a relevant MHC molecule and the peptide presented thereby. For example, as was shown, supra, DAGE derived tumor rejection antigens ("TRAs") are presented by HLA-A24 cells. Thus, by mixing the PBL sample with a target of HLA-A24 presenting cells and peptides which are derived from a TRAP and presented by HLA-A24, one can observe CTL proliferation, and thus diagnose for the presence of transformed cells. These cells can be cells which normally present the MHC molecule in question, but can also be cells transformed by an HLA coding sequence. The cells may be tumor cells, or normal cells. Various ways of determining CTL proliferation are known, including TNF release assays, and ⁵¹Cr release assays. Other methodologies are also available. Thus, one aspect of the invention involves mixing a target cell sample with a peptide or mix of peptides derived from a DAGE TRA and presented by the MHC molecules of the target cell sample and with the PBLs of the subject under evaluation. The mixture is then tested for CTL proliferation.

Th peptide r p ptides may also be combin d with ne r more
adjuvants which stimulate a more pronounced CTL response.
Exemplary of such adjuvants are saponins and their derivatives,
such as those disclosed by U.S. Patent No. 5,057,540 to Kensil t
5 al., incorporated by reference or PCT application PCT/US92/03579
to Scott et al., also incorporated by reference. Of cours ,
standard adjuvants, such as Freund's complete adjuvant, or Freund's
incomplete adjuvant, may also be used.

Other aspects of the invention will be clear to the skill d
10 artisan and need not be repeated here.

The terms and expressions which have been employed are used
as terms of description and not of limitation, and there is no
intention in the use of such terms and expressions of excluding any
equivalents of the features shown and described or portions
15 thereof, it being recognized that various modifications ar
possible within the scope of the invention.

DNA sequence 15 b.p. GACTGAGACCTA ... TCTATGACCCGG 11n.

	10	20	30	40	50	60
1	GACTGAGACC	TAGAAATCCA	AACGTTGAG	GTCCCTGAGOC	CAGCCTAAGT	CGCTTCAAA 60
61	TGGAAAGAAC	GGTTTTCGGG	GGTTCCATTC	AGAGCCGATA	CATCAGCATG	AGTGTGTGCA 120
121	CAAGCCCAAG	GAGACTTGTG	GAGCTGCCAG	GGCAGAGCCT	GCTGAGAGAT	GAGCCCTGTG 180
181	CCATTGCCGC	CCGCGAGTTC	CTGCCCAAGG	ACCTCTTCCC	GCCACTCTTC	ATGCCAGCCT 240
241	TTGACGGGAG	ACACAGCCAG	AACCTGAAAG	CAATGGTCCA	GGCCTGGCCC	TTCACTGTCC 300
301	TCCCTCTGGG	AGTGCAGATG	AAGGGACAAAC	ATCTTCACTT	GGAGACCTTC	AAAGCTGTGC 360
361	TTGATGGACT	TGAGGTGCTC	CTTGGCCAGG	AGGTTCCGCC	CAGGAGCTGG	AAACTTCAG 420
421	TGCTGGATTT	ACGGAAGAAC	TCTCATCAGG	ACTTCTGGAC	TGTATGGTCT	GGAAGCAAGG 480
481	CCAGTCTGTA	CTCAATTCCA	GAGCCAGAG	CAGCTCAGCC	CATGACAAAG	AACTGAAAG 540
541	TAGATGCTTT	GAGCAGAGAG	GCAGAGCAGC	CCTTCATTC	AGTAGAGGTG	CTGGTAGACC 600
601	TGTTCTCTAA	GGAGGTGGC	TGTGATGAAT	TGTTCTCTAA	CCTCATTAAG	AAAGTGAAGC 660
661	GAAAGAAA	TGTACTAACC	CTGTCTGTA	AGAACTGAA	GATTTTCCA	ATGCCCATGC 720
721	AGGATATCAA	GATGATCTG	AAAATGGTGC	AGCTGACTC	TATTAAGAT	TTGGAAGTGA 780
781	CTTGTACTTG	GAACTAACC	ACCTTGGGTA	AATTTCTCC	TTACCTGGC	CAGATGATA 840
841	ATCTGGTAG	ACTGCTCTC	TCCCAATGC	ATGCATCTC	CTACATTC	CCGAGAGAG 900
901	AAGAGCATA	TATGGCCAG	TTCACTCTC	AGTTCTCAG	TCTGCACTC	CTGCAAGCTC 960
961	TCTATGTGA	CTCTTAATTT	TTCTTAGAG	GCCGCTGGA	TCAATTCTC	AGGCAAGTGA 1020
1021	TGAACCCCTT	GGAAACCTC	TCAATACCTA	ACTGCCCCCT	TTGGGAAGG	GATGTATGC 1080
1081	ATCTGTCCA	GAGTCCCTAC	GTCACTCAGC	TAAATGTCT	GAGTCAAGT	GGGTCTATGC 1140
1141	TGAACGATGT	AAGTCCCGAG	CCCTCCAG	CTCTGCTGGA	GAGAGCCTCT	GCACCCCTCC 1200
1201	AGGACCTGGT	CTTTGATGAG	TGTGGATCA	CGATGATCA	GCTCCTTGC	CTCCTGCTTT 1260
1261	CCCTGAGCCA	CTGCTCCAG	CTTACAACT	TAACTTCTA	CGGGAATTC	ATCTCATAT 1320
1321	CTGCTGTCCA	GATCTCTCTG	CAGCACTCA	TCCGCTGAG	CAATCTGAC	CAGCTGCTGT 1380
1381	ATCTGTGCC	CTGAGAGT	TATGAGGACA	TCCATGGTAC	CTTCCACTG	GAGAGGCTTG 1440
1441	CCATCTGCA	TGCCAGCTC	AAGGATTC	TGTGTGATTT	GGGCGGCC	AACATGCTCT 1500
1501	GGCTTAGTGC	CAACCCCTGT	CCTCACTGTG	GGGACAGAAC	CTTCTATGAC	CCGG 1554

(SEQ ID NO. 1)

SL# ID NO. 2

We claim:

1. An isolated nucleic acid molecule consisting essentially of the nucleotide sequence set forth in SEQ ID NO: 1.
2. An isolated nucleic acid molecule consisting essentially of the nucleotide sequence set forth in SEQ ID NO : 2.
3. An isolated nucleic acid molecule which hybridizes, under stringent conditions, to the nucleic acid molecule set forth in SEQ ID NO: 1 or SEQ ID NO : 2, and codes for a tumor rejection antigen precursor, with the proviso that said isolated nucleic acid molecule does not code for any of a MAGE tumor rejection antigen precursor or a BAGE tumor rejection antigen precursor or a GAGE tumor rejection antigen precursor.
4. An isolated nucleic acid molecule consisting of nucleotides 1-1554 of SEQ ID NO: 1.
5. An isolated mRNA molecule which is complementary to the nucleic acid molecule of claim 1.
6. A host cell transfected or transformed with the nucleic acid molecule of claim 1.

7. A host cell transfected or transformed with the nucleic acid molecule of claim 3.
8. A host cell transfected or transformed with the nucleic acid molecule of claim 4.
9. An expression vector comprising the isolated nucleic acid molecule of claim 1 or claim 2, operably linked to a promoter.
10. An expression vector comprising the isolated nucleic acid molecule of claim 3 operably linked to a promoter.
11. An expression vector comprising the isolated nucleic acid molecule of claim 4, operably linked to a promoter.
12. The host cell of claim 6, wherein said host cell is a mammalian cell which expresses HLA-A24.
13. The host cell of claim 7, wherein said host cell is a mammalian cell which expresses HLA-A24.
14. The host cell of claim 8, wherein said host cell is a mammalian cell which expresses HLA-A24.
15. The expression vector of claim 9, further comprising a nucleic acid molecule which codes for HLA-A24.

16. The expression vector of claim 10, further comprising a nucleic acid molecule which codes for HLA-A24.
17. The expression vector of claim 11, further comprising a nucleic acid molecule which codes for HLA-A24.
18. Expression kit comprising a separate portion of each of:
 - (i) the isolated nucleic acid molecule of claim 1 or claim 2, and
 - (ii) a nucleic acid molecule which codes for HLA-A24.
19. Expression kit comprising a separate portion of each of:
 - (i) the isolated nucleic acid molecule of claim 3, and;
 - (ii) a nucleic acid molecule which codes for HLA-A24.
20. Expression kit comprising a separate portion of each of:
 - (i) the isolated nucleic acid molecule of claim 4, and;
 - (ii) a nucleic acid molecule which codes for HLA-A24.
21. An isolated tumor rejection antigen precursor coded for by the nucleic acid molecule of claim 1, 2, 3 or 4.
22. Isolated peptide of SEQ ID NO : 5 or SEQ ID NO : 7.


Figure 1

Figure 1A

Figure 1B

Figure 1C



Figur 2

Figure 3

Stimulator cells	TNF released by CTL 269/17 (pg/ml)			
	10	20	30	40
LB33-MEL.B-1				
COS				
COS + A24				
COS + A24 + cDNA 5E10				

A

Stimulator cells	TNF released by CTL 269/17 (pg/ml)		
	10	20	30
LB33-MEL.B-1	[Bar chart showing high TNF release]		
COS-7	[Bar chart showing low TNF release]		
COS-7 + A24	[Bar chart showing low TNF release]		
COS + A24 + cDNA 5E10	[Bar chart showing high TNF release]		

B**Fig. 4**




Fig. 5




Fig. 6

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/12117**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) r to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.5; 435/240.2, 252.3, 254.11, 320.1; 530/300, 350, 395, 828

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE, BIOSIS, EMBASE, DERWENT WPI, APS, CHEM ABS, search terms: author names, dage, tumor, tumour, hla-a24, antigen, hi2, 5e10, cancer, cDNA, myeloma, trap, testis, ovary, endometrium

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A, P	US, A, 5,405,940 (BOON ET AL.) 11 April 1995, see entire document.	1-22

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A* document defining the general state of the art which is not considered to be of particular relevance	* X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* E* earlier document published on or after the international filing date	* Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* A*	document member of the same patent family
* O* document referring to an oral disclosure, use, exhibition or other means		
* P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

13 NOVEMBER 1995

Date of mailing of the international search report

06 DEC 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

RON SCHWADRON

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/12117

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

C07H 21/04; C12N 5/00, 5/08, 5/10, 1/21, 1/15, 15/00, 15/09, 15/12, 15/63; C07K 14/00, 14/435, 14/47, 14/705, 14/74

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

536/23.5; 435/240.2, 252.3, 254.11, 320.1; 530/300, 350, 395, 828

**CORRECTED
VERSION**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07H 21/04, C12N 5/00, 5/08, 5/10, 1/21, 1/15, 15/00, 15/09, 15/12, 15/63, C07K 14/00, 14/435, 14/47, 14/705, 14/74	A1	(11) International Publication Number: WO 96/10577 (43) International Publication Date: 11 April 1996 (11.04.96)
(21) International Application Number: PCT/US95/12117 (22) International Filing Date: 21 September 1995 (21.09.95) (30) Priority Data: 08/316,231 30 September 1994 (30.09.94) US (60) Parent Application or Grant (63) Related by Continuation US 08/316,231 (CIP) Filed on 30 September 1994 (30.09.94) (71) Applicant (for all designated States except US): LUDWIG INSTITUTE FOR CANCER RESEARCH [CH/US]; 1345 Avenue of the Americas, New York, NY 10105 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): COULIE, Pierre [BE/BE]; Avenue Hippocrate 74, UCL 7459, B-1200 Brussels (BE). IKEDA, Hideyuki [JP/BE]; Avenue Hippocrate 74, UCL 7459, B-1200 Brussels (BE). BOON-FALLEUR, Thierry [BE/BE]; Avenue Hippocrate 74, UCL 7459, B-1200 Brus- sels (BE).		(74) Agent: HANSON, Norman, D.; Felfe & Lynch, 805 Third Avenue, New York, NY 10021 (US). (81) Designated States: AU, CA, CN, FI, JP, NO, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: ISOLATED NUCLEIC ACID MOLECULE CODING FOR TUMOR REJECTION ANTIGEN PRECURSOR DAGE AND USES THEREOF (57) Abstract A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as DAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as GAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigens, and their precursor molecules are described.		

* (Referred to in PCT Gazette No. 25/1996, Section II)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**ISOLATED NUCLEIC ACID MOLECULE CODING FOR TUMOR REJECTION
ANTIGEN PRECURSOR DAGE AND USES THEREOF**

RELATED APPLICATIONS

This application is a continuation in part of application Serial Number 08/316,231, filed September 30, 1994, the disclosure of which is incorporated by reference.

FIELD OF THE INVENTION

This invention relates to a nucleic acid molecule which code for a tumor rejection antigen precursor. More particularly, the invention concerns genes, whose tumor rejection antigen precursor is processed, inter alia, into at least one tumor rejection antigen that is presented by HLA-A24 molecules. The tumor rejection antigen precursor, or "TRAP" may be processed into additional peptides presented by other MHC molecules, such as HLA-A1 and its alleles, HLA-A2, HLA-Cw*1601, HLA-B44, and so forth. The genes in question do not appear to be related to other known tumor rejection antigen precursor coding sequences, are expressed on a variety of tumors and, with the exception of testis, ovary and endometrial cells, are not expressed by normal cells.

BACKGROUND AND PRIOR ART

The process by which the mammalian immune system recognizes and reacts to foreign or alien materials is a complex one. An important facet of the system is the T lymphocyte, or "T cell" response. This response requires that T cells recognize and interact with complexes of cell surface molecules, referred to as human leukocyte antigens ("HLA"), or major histocompatibility

complexes ("MHCs"), and peptides. The peptides are derived from larger molecules which are processed by the cells which also present the HLA/MHC molecule. See in this regard Male et al., Advanced Immunology (J.P. Lipincott Company, 1987), especially chapters 6-10. The interaction of T cells and HLA/peptide complexes is restricted, requiring a T cell specific for a particular combination of an HLA molecule and a peptide. If a specific T cell is not present, there is no T cell response even if its partner complex is present. Similarly, there is no response if the specific complex is absent, but the T cell is present. This mechanism is involved in the immune system's response to foreign materials, in autoimmune pathologies, and in responses to cellular abnormalities. Much work has focused on the mechanisms by which proteins are processed into the HLA binding peptides. See, in this regard, Barinaga, Science 257: 880 (1992); Fremont et al., Science 257: 919 (1992); Matsumura et al., Science 257: 927 (1992); Latron et al., Science 257: 964 (1992).

The mechanism by which T cells recognize cellular abnormalities has also been implicated in cancer. For example, in PCT application PCT/US92/04354, filed May 22, 1992, published on November 26, 1992, and incorporated by reference, a family of genes is disclosed, which are processed into peptides which, in turn, are expressed on cell surfaces, which can lead to lysis of the tumor cells by specific CTLs cytolytic T lymphocytes, or "CTLs" hereafter. The genes are said to code for "tumor rejection antigen precursors" or "TRAP" molecules, and the peptides derived therefrom

are referred to as "tumor rejection antigens" or "TRAs". See Traversari et al., Immunogenetics 35: 145 (1992); van der Bruggen et al., Science 254: 1643 (1991), for further information on this family of genes. Also, see U.S. patent application Serial Number 807,043, filed December 12, 1991, now U.S. Patent No. 5,342,774, incorporated by reference in its entirety. The "MAGE" family of tumor rejection antigen precursors is disclosed in this patent.

In U.S. patent application Serial Number 938,334, now U.S. Patent No. 5,405,940 the disclosure of which is incorporated by reference, it is explained that the MAGE-1 gene codes for a tumor rejection antigen precursor which is processed to nonapeptides which are presented by the HLA-A1 molecule. The nonapeptides which bind to HLA-A1 follow a "rule" for binding in that a motif is satisfied. In this regard, see e.g. PCT/US93/07421; Falk et al., Nature 351: 290-296 (1991); Engelhard, Ann Rev. Immunol. 12: 181-207 (1994); Ruppert et al., Cell 74: 929-937 (1993); Rötzschke et al., Nature 348: 252-254 (1990); Bjorkman et al., Nature 329: 512-518 (1987); Traversari et al., J. Exp. Med. 176: 1453-1457 (1992). The reference teaches that given the known specificity of particular peptides for particular HLA molecules, one should expect a particular peptide to bind to one HLA molecule, but not to others. This is important, because different individuals possess different HLA phenotypes. As a result, while identification of a particular peptide as being a partner for a specific HLA molecule has diagnostic and therapeutic ramifications, these are only relevant for individuals with that particular HLA phenotype. There

is a need for further work in the area, because cellular abnormalities are not restricted to one particular HLA phenotype, and targeted therapy requires some knowledge of the phenotype of the abnormal cells at issue.

5 In U.S. Patent Application Serial Number 008,446, filed January 22, 1993 and incorporated by reference, the fact that the MAGE-1 expression product is processed to a second TRA is disclosed. This second TRA is presented by HLA-Cw*1601 molecules. The disclosure shows that a given TRAP can yield a plurality of
10 TRAs, each of which will satisfy a motif rule for binding to an MHC molecule.

In U.S. Patent Application Serial Number 994,928, filed December 22, 1992, and incorporated by reference herein teaches that tyrosinase, a molecule which is produced by some normal cells
15 (e.g., melanocytes), is processed in tumor cells to yield peptides presented by HLA-A2 molecules.

In U.S. patent application Serial No. 08/032,978, filed March 18, 1993, and incorporated by reference in its entirety, a second TRA, not derived from tyrosinase is taught to be presented by HLA-
20 A2 molecules. The TRA is derived from a TRAP, but is coded for by a non-MAGE gene. This disclosure shows that a particular HLA molecule may present TRAs derived from different sources.

In U.S. patent application Serial No. 08/079,110, filed June 17, 1993 and incorporated by reference herein, an unrelated tumor
25 rejection antigen precursor, the so-called "BAGE" precursor is described. The BAGE precursor is not related to the MAGE family.

In U.S. patent applications Serial No. 08/096,039 and Serial No. 08/250,162, both of which are incorporated by reference, non-related TRAP precursor GAGE is also disclosed.

The work which is presented by the papers, patent, and patent applications cited supra deals, in large part, with the MAGE family of genes, and the unrelated BAGE and GAGE genes. It has now been found, however, that additional tumor rejection antigen precursors are expressed by cells. These tumor rejection antigen precursors are referred to as "DAGE" tumor rejection antigen precursors. They do not show homology to the MAGE family of genes, the BAGE gene, or the GAGE gene. Thus the present invention relates to genes encoding such TRAPs, the tumor rejection antigen precursors themselves as well as applications of both.

What further characterizes the DAGE tumor rejection antigen precursors is that their expression by tumor cells is much more widespread than the other tumor rejection antigen precursors described previously. This is proven infra. Yet, the expression of the family by normal cells is again limited to testis, ovary and endometrial cells. Thus, a much more general means of assaying for the presence of transformed cells is available than previously. This will be seen by way of the examples.

The invention is elaborated upon further in the disclosure which follows.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 describes, collectively, ^{51}Cr release, cell lysis studies. In particular:

Figure 1A shows lysis of cell line LB33-MEL.B-1;

5 Figure 1B shows lysis of LB33 B cells transformed by EBV. These are autologous cells.

Figure 1C shows lysis studies on NK target K562. In each case, the effector cells were CTL clone LB33-CTL-269/17.

10 Figure 2 presents studies on the inhibition of lysis by cytolytic T cells in the presence of an anti-HLA-A24 monoclonal antibody. The studies were carried out in the presence or absence of 30 fold dilutions of culture medium of a hybridoma producing the HLA-A24 specific monoclonal antibody.

15 Figures 3A & 3B show the result of lysis experiments following transfection of LB804-ALL cells with the sequence H12.

20 Figure 4 shows the results obtained in a TNF release assay using CTL 269/17. The stimulator cells were either LB33-MEL.B-1, COS-7 cells, COS-7 cells tranfected with a cDNA sequence coding for HLA-A24, or COS-7 cells transfected with both cDNA sequence coding for HLA-A24, and cDNA coding for a tumor rejection antigen precursor in accordance with this invention.

Figure 5 compares induced lysis using various peptides derived from DAGE.

25 Figure 6 shows the expression of DAGE in various tissue samples.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS**Example 1**

Melanoma cell line LB33-MEL.B was derived from a metastasis of patient LB33, using standard techniques. Tumor cells were then
5 cloned by limiting dilution, resulting in clone LB33-MEL.B-1, used hereafter.

Samples containing mononuclear blood cells (which include lymphocytes) were taken from patient LB33. Samples of clone LB33-MEL.B-1 were contacted to the mononuclear blood cell samples. The
10 mixtures were observed for lysis of the LB33-MEL.B-1 cells, this lysis indicating that cytolytic T cells ("CTLs") specific for a complex of peptide and HLA molecule presented by the cells were present in the sample.

The lysis assay employed was a chromium release assay
15 following Herin et al., Int. J. Cancer 39:390-396 (1987), the disclosure of which is incorporated by reference. The assay, however, is described herein. The target melanoma cells were grown in vitro. Prior to labelling, these cells were incubated for 48 hours, in the presence of 50 U/ml of IFN- γ to increase the
20 expression of HLA Class I molecules. The cells were then resuspended at 10^7 cells/ml in DMEM, supplemented with 10 mM HEPES and 30% FCS (i.e. fetal calf serum), and incubated for 45 minutes at 37°C with 200 μ Ci/ml of Na(51 Cr)O $_4$. Labelled cells were washed three times with DMEM, supplemented with 10 mM Hepes. These were

then r susp nded in DMEM supplemented with 10 mM Hepes and 10% FCS, after which 100 ul aliquots containing 10^3 cells, were distributed into 96 well microplates. PBL containing samples were added in 100 ul of the same medium, and assays were carried out in duplicat .
5 Plates were centrifuged for 4 minutes at 100g, and incubated for four hours at 37°C in a 5.5% CO₂ atmosphere.

Plates were centrifuged again, and 100 ul aliquots of supernatant were collected and counted. Percentage of ⁵¹Cr release was calculated as follows:

10
$$\% \text{ } ^{51}\text{Cr release} = \frac{(\text{ER}-\text{SR})}{(\text{MR}-\text{SR})} \times 100$$

where ER is observed, experimental ⁵¹Cr release, SR is spontaneous release measured by incubating 10^3 labeled cells in 200 ul of medium alone, and MR is maximum release, obtained by adding 100 ul
15 0.3% Triton X-100® to target cells.

Those mononuclear blood cell samples which showed high CTL activity were expanded and cloned via limiting dilution, and were screened again, using the same methodology.

The same method was used to test target K562 cells. When
20 EBV-B cells were used, the only change was the replacement of DMEM medium by Hank's medium, supplemented with 5% FCS.

These experiments led to isolation of CTL clone LB33-CTL-269/17 from patient LB33. As figures 1A-1C indicate, this CTL clone lysed LB33-MEL.B-1 tumor cells, but not EBV transformed B
25 c lls of patient LB33, nor K562 cells. Wh n the target c lls wer

incubated with a monoclonal antibody specific to HLA-A24, lysis was inhibited, suggesting that any TRA peptide involved is presented by HLA-A24. Figure 2 shows these results.

A second CTL clone, referred to as LB33-CTL-269/1, lysed LB33-MEL.B-1 but not EBV-B transformed B cells nor K562, thus suggesting that the same target antigen was recognized. Lysis by clone LB33-CTL-269/1 was also inhibited by the anti-HLA-A24 monoclonal antibody.

Example 2

Having identified the presenting MHC molecule as HLA-A24, studies were carried out to identify the coding sequence for the protein molecule, referred to hereafter as the "tumor rejection antigen precursor" or "TRAP" molecule which was the source of the presented peptide.

To do this, total RNA was isolated from cell line LB33-MEL.B-1. The mRNA was isolated using an oligo-dT binding kit, following well recognized techniques. Once the mRNA was secured, it was transcribed into cDNA, again using standard methodologies. The cDNA was then ligated to EcoRI adaptors and cloned into the EcoRI site of plasmid pcDNA-I/Amp, in accordance with manufacturer's instructions. The recombinant plasmids were then electroporated into DH5 α *E. coli* (electroporation conditions: 1 pulse at 25 μ farads, 2500 V).

The transfected bacteria were selected with ampicillin (50 μ g/ml), and then divided into 400 pools of 100 clones each. Each

p 1 represent d ab ut 50 different cDNAs, as analysis showed that all plasmids contained an insert and cloning was not directional. Each pool was amplified to saturation, and plasmid DNA was isolated via alkaline lysis, potassium acetate precipitation and phenol
5 extraction, following Maniatis et al., in Molecular Cloning: A Laboratory Manual (Cold Spring Harbor, N.Y., 1982). Cesium gradient centrifugation was not used.

Example 3

The amplified plasmids were then transfected into eukaryotic
10 cells. Samples of COS-7 cells were seeded, at 15,000 cells/well into tissue culture flat bottom microwells, in Dulbecco's modified Eagles Medium ("DMEM") supplemented with 10% fetal calf serum. The cells were incubated overnight at 37°C, medium was removed and then replaced by 30 µl/well of DMEM medium containing 10% Nu serum, 400
15 µg/ml DEAE-dextran, 100 µM chloroquine, 100 ng of plasmid pcDNA-I/Amp-A2A and 100 ng of DNA of a pool of the cDNA library described supra. Plasmid pcDNA-I/Amp-A24 contains the HLA-A24 gene from LB33-MEL.B which was identified as allele HLA-A*2402. Following four hours of incubation at 37°C, the medium was removed, and
20 replaced by 50 µl of PBS containing 10% DMSO. This medium was removed after two minutes and replaced by 200 µl of DMEM supplemented with 10% of FCS.

Following this change in medium, COS cells were incubated for 48 hours at 37°C. Medium was then discarded, and 2000 cells of described CTL clone 269/1 were added, in 100 µl of Iscove's medium
25

c ntaining 10% pooled human serum. Supernatant was removed after 24 hours, and TNF content was determined in an assay on WEHI cells, as described by Traversari et al., Immunogenetics 35: 145-152 (1992), the disclosure of which is incorporated by reference.

5 Of 400 pools tested, one was positive.

Example 4

The bacteria of the positive pool were subcloned. Plasmid DNA was extracted from 600 individual colonies, and cotransfected with pcDNA-I/Amp-A24 into new samples of COS cells in the same manner
10 as described supra, and the cells were again tested for stimulation of CTL 269/1. A positive clone was found, identified as "5E10".

The plasmid from the positive clone was removed, and sequenced following art known techniques.

The sequence identified is 1554 base pairs long (see SEQ ID
15 NO: 1). This sequence contains an open reading frame encoding 518 amino acids.

The 104 nucleotides at positions 1310-1413 were found to be identical to the 104 first base pairs of a 113 base pair sequence recorded in Genbank: L25344, HOMRBCESTC "Human (clone 17)"
20 erythroleukemic expressed sequence tag (EST) mRNA fragment. No sequences were found which corresponded to the sequence of SEQ ID NO: 1, however.

Example 5

Following the isolation of 5E10, described supra, it was used as a probe in a standard Northern Blot, using total RNA of LB 33-MEL, and standard techniques.

5 The results showed a band of about 2.5 kilobases, which is, of course, somewhat longer than the probe itself. This suggests that clone 5E10 is not complete.

10 As a result, the same cDNA library prepared from RNA of LB33-MEL cells was screened, again using cDNA 5E10 as a probe. A cDNA clone of 2148 base pairs was identified, and sequenced. It is referred to as Hi2. The sequence of 5E10 is completely included in that of Hi2, except that at base 254, Hi2 has cytosine, while 5E10 has thymine.

Example 6

15 Following the isolation of Hi2, a set of experiments were carried out in order to confirm that Hi2 was a tumor rejection antigen precursor encoding sequence. Specifically, HLA-A24 positive leukemia cell line LB804-ALL was used, because prior experiments had shown that CTL 269/17, described supra, did not lyse
20 this line.

 Cells of the leukemia line were transfected with expression vector pEF-BOS-puro.PL3, which carries a gene conferring puromycin resistance, and into which cDNA Hi2 was cloned. Puromycin resistant populations were selected, and isolated. This proved
25

to be sensitive to CTL 269/17, thus indicating that expression of antigen LB33-E is not dependent upon the high copy number which results from COS-7 transfection.

Figures 3A and 3B show these results, where 3A shows the leukemia cell line before transfection, where CTL 269/17 is the responder.

The sequence of Hi2 is provided as SEQ ID NO:2. When comparing it to other sequences in data banks, it was found that nucleotides 1486-1589 are identical to 104 base pairs of a 113 base pair sequence expressed in myeloid leukemia cell line K562 (Gen Bank:L25344). Nucleotides 1983-2128 are identical to 146 of 147 base pairs expressed in promyelocytic leukemia cell line. HL-60 (DDBJ:D20455), while nucleotides 1736-2067 are 97% homologous with 325 base pairs of a 332 base pair cDNA found in cells of human testis (Gen Bank:T19428).

Analysis of the sequence of Hi2 shows an open reading frame encoding a putative protein of 509 amino acids, which has no signal sequence. No significant homology was found with other protein sequences in data banks.

Example 7

Hi2 was then used to isolate genomic DNA encoding the pertinent protein. The DNA of 12 groups of 70,000 cosmids of a human genomic DNA library was collected, and 5E10 was used to hybridize to these, using standard methodologies. The clone hybridized to one cosmid group. Following subcloning the cosmid

was identified which hybridized with cDNA clone 5E10. The sequence was secured by using primers deduced from the cDNA sequence. The sequence presents six exons, with the open reading frame spanning exons 3-6.

5 **Example 8**

The information in SEQ ID NO: 1 was sufficient to permit analysis of gene expression via polymerase chain reaction (PCR).

The following primers were used:

10 5'-GCCTGCTGAAGGATGAGGCC-3'
 (SEQ ID NO: 3)

5'-GGTGCTGCAGGAGACTCTGC-3'
 (SEQ ID NO: 4)

These correspond to nucleotides 157-176, and 1328-1347 of SEQ ID NO: 1, respectively.

15 The PCR was carried out for 28 cycles, (1 cycle: 1 minute 94°C, 2 minutes at 65°C, 3 minutes at 72°C). In carrying out the PCR, 2.5 ul of cDNA template, prepared as described supra, was combined with 2.5 ul of 10x Dynazyme buffer, 0.25 ul of each dNTP (10 mM), 0.5 ul of each primer (20 mM), 0.5U Dynazyme (0.25 ul stock, 2 U/ml),
20 and 18.5 ul water. Table 1, which follows, sets forth the results. Note the expression over a number of varied tumor samples, as well as tumor cell lines, indicating that this is not an artifact of cell culture. Further, with the exception of testis, there is absolutely no expression in normal tissues.

Table 1

Expression of the gene corresponding to cDNA clone 5E10 in tumors and normal tissues

Normal tissues:

Liver	0/1
Stomach	0/1
Colon	0/1
Lung	0/1
Spleen	0/1
Heart	0/1
Breast	0/1
Bladder	0/1
Prostate	0/1
Thymus	0/1
Bone marrow	0/1
Blood lymphocytes	0/1
Fibroblasts	0/1
Testis	2/2

Tumor samples:

Melanoma	5/5
Lymphoma	2/5
Chronic Myeloid Leukemia	1/2
Chronic Lymphoid Leukemia	1/5
Acute Myeloid Leukemia	0/6
Renal Carcinoma	3/6
Sarcoma	2/3
Breast carcinoma	2/5

Tumor cell lines:

Melanoma	11/15
Leukemia	3/6
Burkitt lymphoma	2/4

Example 9

A second assay was carried out, based upon TNF (tumor necrosis factor) release. In this assay, COS-7 cells (10,000 cells/mirowell) were transfected with the plasmid pcDNAI/Amp carrying HLA-A24 cDNA, as described supra, or cotransfected with this plasmid and plasmid pcDNAI/Amp containing SEQ ID NO: 1, described supra. Twenty four hours after transfection, 3000 cells of CTL 269/17 were added to the transfectants. In a control, the same number of LB33-MEL.B-1 cells were used. The concentration of TNF released in the cell medium was measured after 24 hours, using TNF sensitive cell line WEHI-164c13.

The results are presented in figure 4. They show that TNF release by CTLs was provoked only with COS cells cotransfected with vectors expressing HLA-A24 and SEQ ID NO 1. COS cells do not present HLA-A24 on their own, nor do they express the sequences of the invention. When cotransfected, however, they were able to provoke TNF release to a level nearly that of autologous cell line LB33-MEL.B-1.

The results, as set forth in figure 3, not only show that the material of SEQ ID NO: 1 does in fact code for a tumor rejection antigen precursor which stimulates CTLs when processed, it also shows that, as elaborated upon infra, one can assay for the presence of CTLs which are specific for tumor cells by using non-transformed cells, such that the resulting transfectant will express both HLA-A24 and DAGE.

Example 10

As it has been well established that TRAPs are processed to smaller tumor rejection antigens, experiments were undertaken to identify a tumor rejection antigen or antigens produced from the described sequences.

The cDNA for 5E10 was partially digested with the endonuclease NsiI, and the thus truncated cDNA clones were cotransfected into COS-7 cells with HLA-A24 cDNA clones. Transfectants were then tested for expression of LB33-E, by adding CTL 269/17, and measuring TNF production.

Results are summarized in figure 5. Nucleotides corresponding to nucleotides 1047-1260 of the cDNA of Hi2 were found to encode the relevant antigen. Four sequences in this region which (i) were 9 or 10 amino acids long, (ii) had Tyr or Phe at position 2, and (iii) had one of Phe, Leu, Ile, or Trp at C-terminus were possible. This is the motif for HLA-A24 binding described by Kubo, et al, J. Immunol 152:3913 (1994); Meier, et al, Immunogenetics 40:306-308 (1994). These were synthesized, and incubated with cells of MHC class I negative B-cell lymphoblastoid line C1R, which had been transfected with the HLA-A24 cDNA clone described supra. One peptide:

Leu Tyr Val Asp Ser Leu Phe Phe Leu (SEQ ID NO. 5), was found to sensitize the transfected C1R-A24 cells to lysis by the anti LB33-E CTLs, with half maximal effect at 500 nM.

Comparativ experiments were carried out, wherein peptides containing one additional N- or C-terminal amino acid, and where the C-terminal Leu was deleted, were used. SEQ ID NO:7 sensitized the cells to lysis, although to a lesser degree than SEQ ID NO:5. SEQ ID NOS : 8 and 9 were much less sensitive in sensitizing th cells, as is shown in figure 6. Peptides used extended SEQ ID NO:5 at the N-terminus with Ala (SEQ ID NO:7), and by deleting the C-terminal Leu (SEQ ID NO:8). Addition of Arg to the C terminus resulted in SEQ ID NO:9. In these experiments, ⁵¹Cr labeled C1R-A24 cells were incubated for 30 minutes in the presence of indicated peptide concentrations CTLs were added at E/T ratios of 10:1, and chromium release was measured after 4 hours.

Example 11

Tests were then carried out, using the well known revers transcriptase polymerase chain reaction ("RT-PCR"), to determin expression of the subject gene. In table 2, which follows the results are shown.

The higher proportion of positive tumors were melanomas (91%), lung squamous carcinomas (78%), and adenocarcinomas (46%), as well as renal carcinomas (43%), sarcomas (40%), and acute leukemias (33%).

There was also some expression in normal tissues. Testis, ovary, and endometrium expressed about 10% of what was found in cell lin LB33-MEL, while lower levels wer found in skin, brain, h art, kidn y, and adrenal tissue. N t Tabl 2 and figur 6.

Table 2. Expression of gene DAGE by tumoral tissues.

Tumor samples

Brain tumors		1/7	
Colorectal carcinomas		2/51	4%
Gastric carcinomas		1/2	
Naevi		9/18	
Melanomas	primary lesions	43/49	88%
	metastases	144/152	95%
	ocular	5/9	
Neuroblastomas		2/3	
Head and neck squamous carcinomas		17/44	39%
Lung carcinomas	SCLC	1/4	
	NSCLC	12/26	46%
	adenocarcinomas	51/65	78%
	squamous carcinomas	2/20	
Prostatic carcinomas		24/56	43%
Renal carcinomas		4/36	11%
Bladder tumors	superficial	9/42	21%
	infiltrating	10/25	40%
Sarcomas		45/169	27%
Mammary carcinomas		3/5	
Thyroid carcinomas		21/63	33%
Acute leukemias			

Tumor cell lines

Melanomas		72/74	97%
Sarcomas		4/5	
Lung carcinomas	SCLC	19/27	70%
	NSCLC	2/2	
Mesotheliomas		2/18	
Head and neck tumors		2/7	
Bladder tumors		2/3	
Colorectal carcinomas		1/15	
Renal carcinomas		9/12	
EBV-transformed lymphoblastoid B cell lines		0/8	

Th f r going examples show the isolation of a nucleic acid molecule which codes for a tumor rejection antigen precursor. This "TRAP" coding molecule, however, is not homologous with any of the previously disclosed MAGE, BAGE or GAGE coding sequences described in the references set forth supra. Hence, one aspect of the invention is an isolated nucleic acid molecule having the nucleotide sequence set forth in SEQ ID NO : 1 or SEQ ID NO : 2, as well as those portions of SEQ ID NO: 1 or SEQ ID NO:2 which express TRAs such as those encoding SEQ ID NOS : 5, 7 and 9 presented by MHC molecules such as HLA-A24, and derived from DAGE. This sequence is not a MAGE, BAGE or GAGE coding sequence, as will be seen by comparing it to the sequence of any of these genes as described in the cited references. Also a part of the invention are those nucleic acid sequences which also code for a non-MAGE, non-BAGE and non-MAGE tumor rejection antigen precursor but which hybridize to the nucleic acid molecule having the nucleotide sequence of SEQ ID NO: 1 and/or 2 under stringent conditions. Th term "stringent conditions" as used herein refers to parameters with which the art is familiar. More specifically, stringent conditions, as used herein, refers to hybridization in 1M NaCl, 1% SDS, and 10% dextran sulfate. This is followed by two washes of the filter at room temperature for 5 minutes, in 2xSSC, and on wash for 30 minutes in 2xSSC, 0.1% SDS. There are oth r conditions, reagents, and so forth which can be used, which result in the same or higher d gre of stringency. The skill d

artisan will be familiar with such conditions, and, thus, they are not given here.

The widespread distribution in the expression of this gene (7 out of 8 types of tumor were found to express it), shows that the isolated nucleic acid molecule can be used as a diagnostic probe to determine presence of transformed cells. The identification of melanoma was 100%, so on a very basic level, the isolated nucleic acid molecules may be used to determine whether or not melanoma is present. Note that there are many ways available to the skilled artisan to confirm that a tumor sample is a melanoma sample, and these need not be reiterated here. Further, the rate of success in identifying tumors is in accordance with nucleic acid based diagnostic methods for determining transformation of cells.

It will also be seen from the examples that the invention embraces the use of the sequences in expression vectors, which may be used to transform or to transfect host cells and cell lines, be these prokaryotic (e.g., *E. coli*), or eukaryotic (e.g., CHO or COS cells). The expression vectors require that the pertinent sequence, i.e., those described supra, be operably linked to a promoter. As it has been found that human leukocyte antigen HLA-A24 presents a tumor rejection antigen derived from these genes, the expression vector may also include a nucleic acid sequence coding for HLA-A24. In a situation where the vector contains both coding sequences, it can be used to transform or transfect a cell which does not normally express either one. The tumor rejection antigen precursor coding sequence may be used alone, when, e.g.,

the host cell already expresses HLA-A24. Of course, there is no limit on the particular host cell which can be used. As the vectors which contain the two coding sequences may be used in HLA-A24 presenting cells if desired, and the gene for tumor rejection antigen precursor can be used in host cells which do not express HLA-A24.

The invention also embraces so called expression kits, which allow the artisan to prepare a desired expression vector or vectors. Such expression kits include at least separate portions of each of the previously discussed coding sequences. Other components may be added, as desired, as long as the previously mentioned sequences, which are required, are included.

To distinguish the nucleic acid molecules and the TRAPs of the invention from the previously described MAGE, BAGE and GAGE materials, the invention shall be referred to as the DAGE family of genes and TRAPs. Hence, whenever "DAGE" is used herein, it refers to the tumor rejection antigen precursors coded for by the previously described sequences. "DAGE coding molecule" and similar terms, are used to describe the nucleic acid molecules themselves.

The invention as described herein has a number of uses, some of which are described herein. First, the invention permits the artisan to diagnose a disorder characterized by expression of the TRAP. These methods involve determining expression of the TRAP gene, and/or TRAs derived therefrom, such as a TRA presented by HLA-A24. In the former situation, such determinations can be carried out via any standard nucleic acid determination assay,

including the polymerase chain reaction, or assaying with labelled hybridization probes. In the latter situation, assaying with binding partners for complexes of TRA and HLA, such as antibodies, is especially preferred. An alternate method for determination is a TNF or ^{51}Cr release assay, of the types described supra.

The isolation of the TRAP gene also makes it possible to isolate the TRAP molecule itself, especially TRAP molecules containing the amino acid sequence coded for by SEQ ID NO: 2. These isolated molecules when presented as the TRA, or as complexes of TRA and HLA, such as HLA-A24, may be combined with materials such as adjuvants to produce vaccines useful in treating disorders characterized by expression of the TRAP molecule. In addition, vaccines can be prepared from cells which present the TRA/HLA complexes on their surface, such as non-proliferative cancer cells, non-proliferative transfectants, etcetera. In all cases where cells are used as a vaccine, these can be cells transfected with coding sequences for one or both of the components necessary to provide a CTL response, or be cells which express both molecules without transfection. Further, the TRAP molecule, its associated TRAs, as well as complexes of TRA and HLA, may be used to produce antibodies, using standard techniques well known to the art.

When "disorder" is used herein, it refers to any pathological condition where the tumor rejection antigen precursor is expressed. An example of such a disorder is cancer, melanoma in particular. Melanoma is well known as a cancer of pigment producing cells.

Therapeutic approaches based upon the disclosure are premised on a response by a subject's immune system, leading to lysis of TRA presenting cells, such as HLA-A24 cells. One such approach is the administration of CTLs specific to the complex to a subject with abnormal cells of the phenotype at issue. It is within the skill of the artisan to develop such CTLs in vitro. Specifically, a sample of cells, such as blood cells, are contacted to a cell presenting the complex and capable of provoking a specific CTL to proliferate. The target cell can be a transfectant, such as a COS cell of the type described supra. These transfectants present the desired complex on their surface and, when combined with a CTL of interest, stimulate its proliferation. COS cells, such as those used herein are widely available, as are other suitable host cells.

To detail the therapeutic methodology, referred to as adoptive transfer (Greenberg, J. Immunol. 136(5): 1917 (1986); Riddell et al., Science 257: 238 (7-10-92); Lynch et al., Eur. J. Immunol. 21: 1403-1410 (1991); Kast et al., Cell 59: 603-614 (11-17-89)), cells presenting the desired complex are combined with CTLs leading to proliferation of the CTLs specific thereto. The proliferated CTLs are then administered to a subject with a cellular abnormality which is characterized by certain of the abnormal cells presenting the particular complex, where the complex contains the pertinent HLA molecule. The CTLs then lyse the abnormal cells, thereby achieving the desired therapeutic goal.

Forgoing therapy assumes that at least some of the subject's abnormal cells present the relevant HLA/TRA complex.

This can be determined very easily, as the art is very familiar with methods for identifying cells which present a particular HLA molecule, as well as how to identify cells expressing DNA of the pertinent sequences, in this case a DAGE sequence. Once cells
5 presenting the relevant complex are identified via the foregoing screening methodology, they can be combined with a sample from a patient, where the sample contains CTLs. If the complex presenting cells are lysed by the mixed CTL sample, then it can be assumed that a GAGE derived, tumor rejection antigen is being presented,
10 and the subject is an appropriate candidate for the therapeutic approaches set forth supra.

Adoptive transfer is not the only form of therapy that is available in accordance with the invention. CTLs can also be provoked in vivo, using a number of approaches. One approach,
15 i.e., the use of non-proliferative cells expressing the complex, has been elaborated upon supra. The cells used in this approach may be those that normally express the complex, such as irradiated melanoma cells or cells transfected with one or both of the genes necessary for presentation of the complex. Chen et al., Proc.
20 Natl. Acad. Sci. USA 88: 110-114 (January, 1991) exemplifies this approach, showing the use of transfected cells expressing HPV E7 peptides in a therapeutic regime. Various cell types may be used. Similarly, vectors carrying one or both of the genes of interest may be used. Viral or bacterial vectors are especially preferred.
25 In these systems, the gene of interest is carried by, e.g., a Vaccinia virus or the bacteria BCG, and the materials de facto

"infect" host cells. The cells which result present the complex of interest, and are recognized by autologous CTLs, which then proliferate. A similar effect can be achieved by combining the tumor rejection antigen or the precursor itself with an adjuvant to facilitate incorporation into HLA-A24 presenting cells which then present the HLA/peptide complex of interest. The TRAP is processed to yield the peptide partner of the HLA molecule while the TRA is presented without the need for further processing.

Also a feature of this invention are isolated peptides derived from the DAGE TRAP which conform to the rules for presentation by MHC molecules. For example, in PCT application No. PCT/US93/07421, incorporated by reference herein, several motifs are described as being associated with different MHC molecules. These motifs, incorporated by reference herein, as well as those taught by, e.g. Falk et al., Nature 351: 290-296 (1991); Engelhard, Ann. Rev. Immunol 12: 181-207 (1994); Ruppert et al., Cell 74: 929-937 (1993); Röttschke et al., Nature 348: 252-254 (1990); Bjorkman et al., Nature 329: 512-518 (1987) and Traversari et al., J. Exp. Med. 176: 1453-1457 (1992) all of which are incorporated by reference, serve as a basis for identifying appropriate peptides obtainable or derivable from the DAGE gene. These peptides may be used alone, or in mixtures, in another aspect of the invention, which is now described. Exemplary of these are the following. For HLA-A2, a binding motif is Xaa Leu Xaa Gly (Xaa)_n Leu (SEQ ID NO : 10) where n is 4 or 5. Amino acids 120-128 of SEQ ID NO : 1 correspond to this motif. A second motif for HLA-A2 replaces terminal Leu with

Val (SEQ ID NO : 3), and amino acids 375-384 satisfy this motif. For HLA-A3, the motifs are Xaa Leu (Xaa)₆ (Lys or Tyr) (SEQ ID NO : 11 and SEQ ID NO : 12). Amino acids 48-56, 100-108, 138-146, 214-222, and 257-265 of SEQ ID NO : 1 well satisfy this motif. For HLA-A11, the motif (Xaa)₇ Lys Lys (SEQ ID NO : 13) is known, and amino acids 169-178, 214-223, and 223-232 will satisfy it. For HLA-A24, the known motif is Xaa Tyr (Xaa)₆ Leu, (SEQ ID NO : 13) and is satisfied by amino acids 274-282, and 467-475 as well as SEQ ID NO : 5. For HLA-B7, the motif is Xaa Pro Arg (Xaa)₅ Leu, (SEQ ID NO : 14) and amino acids 68-76 meet it. For HLA-B8, (Xaa)₂ Lys Xaa Lys (Xaa)₃ Leu (SEQ ID NO : 15) is the motif, satisfied by amino acids 176-184 and 218-226. For HLA-B44, motif Xaa Glu (Xaa)₃ Asp (Xaa)₂ Phe (SEQ ID NO : 16) is satisfied by amino acids 204-212. For HLA-Cw*1601 is satisfied by amino acids 60-68, and 395-403.

The fact that a number of sequences are present which correspond to HLA motifs suggests what will be referred to herein as "cocktail" therapeutic and diagnostic uses. It is expected that in a typical CTL response to tumor cells, CTLs specific to more than one complex of peptide and HLA molecule will proliferate. For example, it may be the case that for HLA-A24 presenting cells, CTLs specific for HLA-A24 and amino acid sequence 467-475 will proliferate. Thus, one can optimize the assay by using both peptides when attempting to identify CTLs. Similarly, the therapeutic methods might be optimized by using more than one HLA-A24 binding peptide.

It is well known that individuals are not "monovalent" for HLA molecules, as cells present more than one kind of HLA. Thus, one can maximize diagnostic and/or therapeutic by combining a number of peptides as described supra in a diagnostic assay to determine CTLs, or to treat patients in the therapies described supra.

Any concern as to false positives, is believed to be misplaced because, as noted supra, the nucleic acid molecules of the invention have been found to be expressed only in tumor cells, so the presence of CTLs to the HLA and the peptides must be considered de facto evidence of the presence, at some time in the past of the present existence of a cancerous or transformed condition. Thus, cocktails of the peptides of the invention can be prepared. Determination of the components of the mixture is not difficult, because all that is needed is one or more of the HLA types presented by the individual under consideration. HLA typing is a very standard technique, well known in the art; and well within the abilities and skill of the artisan.

It has been fairly well established that the blood of individuals afflicted with tumors frequently contains cytolytic T cells ("CTLs") against complexes of MHC molecules and presented peptides. See, e.g., Robbins et al., Canc. Res. 54: 3124-3126 (1994); Topollian et al., J. Immunol. 142: 3714-3725 (1989); Couli et al., Int. J. Cancer 50: 289-297 (1992), all of which are incorporated by reference. Also, note Kawakami et al., J. Exp. Med. 180: 347-352 (1994); H m t al., J. Immun th r 10: 153-164 (1991), Darrow et al, J. Immun l. 142(9): 3329-3335 (1989); Slovin

t al., J. Immunol. 137(9): 3042-3048 (1986), all of which are incorporated by reference. These papers all establish the usefulness of a CTL proliferation assay to diagnose cancer. Expressed generally, one takes a peripheral blood lymphocyte (PBL) containing sample from a subject to be tested. Assuming that the patient does have a tumor, or the subject's cells have begun to undergo transformation, CTLs which are specific to transformed cells will be contained in that sample. These CTLs can be stimulated to proliferate via contact with a target cell which presents complexes of a relevant MHC molecule and the peptide presented thereby. For example, as was shown, supra, DAGE derived tumor rejection antigens ("TRAs") are presented by HLA-A24 cells. Thus, by mixing the PBL sample with a target of HLA-A24 presenting cells and peptides which are derived from a TRAP and presented by HLA-A24, one can observe CTL proliferation, and thus diagnose for the presence of transformed cells. These cells can be cells which normally present the MHC molecule in question, but can also be cells transformed by an HLA coding sequence. The cells may be tumor cells, or normal cells. Various ways of determining CTL proliferation are known, including TNF release assays, and ⁵¹Cr release assays. Other methodologies are also available. Thus, one aspect of the invention involves mixing a target cell sample with a peptide or mix of peptides derived from a DAGE TRA and presented by the MHC molecules of the target cell sample and with the PBLs of the subject under evaluation. The mixture is then tested for CTL proliferation.

Th p ptid r p ptides may also be combined with one or more
adjuvants which stimulate a more pronounced CTL response.
Exemplary of such adjuvants are saponins and their derivatives,
such as those disclosed by U.S. Patent No. 5,057,540 to Kensil et
5 al., incorporated by reference or PCT application PCT/US92/03579
to Scott et al., also incorporated by reference. Of course,
standard adjuvants, such as Freund's complete adjuvant, or Freund's
incomplete adjuvant, may also be used.

Other aspects of the invention will be clear to the skill d
10 artisan and need not be repeated here.

The terms and expressions which have been employed are used
as terms of description and not of limitation, and there is n
intention in the use of such terms and expressions of excluding any
equivalents of the features shown and described or portions
15 thereof, it being recognized that various modifications are
possible within the scope of the invention.

DNA sequence 15 b.p. GACTGAGACCTA ... TCTATGACCCGG 11n.

	10	20	30	40	50	60
1	GACTGAGACC	TAGAAATCCA	AGCGTTGGAG	GTCTGTAGGC	CAGCCTAAGT	CGCTTCAAAA 60
61	TGGACGAAC	CGGTTTGGGG	GGTTCCATTC	AGAGCGGATA	CATCAGCATG	AGTGTGTGGA 120
121	CAAGCCCAAG	GAGACTTGTG	GAGCTGGCAG	GGCAGAGCCT	GCTGAAGGAT	GAGGCGCTTG 180
181	CCATTGCCCC	CCTGGAGTTC	CTGCCCAGGG	ACCTCTTCCC	GCCACTCTTC	ATGCCAGCCT 240
241	TTGACGGGAG	ACAACAACAG	AGCCTGAGAG	CAATGGTGCA	GGCCTGGGCG	TTCACTTGCC 300
301	TCCCTCTGGG	AGTCTGATG	AGGGGACAC	ATCTTCACTT	GAGAACCTTC	AAAGCTGTGC 360
361	TTGATGCACT	TGATGTGCTC	CTTCCCCAGG	AGTTTCCGCG	CAGCAGCTGG	AAACTTCAGG 420
421	TGCTGGATT	ACGTAAGAAC	TCTCATCAGG	ACTTCTGGAC	TGTATGGTCT	GGAAACAGCG 480
481	CCAGTCTGTA	CTCAATTCCA	GAGCCAGAGG	CAGCTCAGCC	CATGACAAAG	AAAGGAAAGG 540
541	TAGATGGTTT	GAGCAACAGG	GCAGACAGAC	CCTTCATTCC	AGTAGAGGTG	CTCCTAGAAC 600
601	TGTTCTCTCA	GGAAAGGTGC	TGTGTGTAAT	TGTTCTCTCA	CTTCATTGAG	AAAGTGAAAC 660
661	GAAAGAAAAA	TGTACTAACG	CTGTCTGTGA	AGAACTGAA	GATTTTTCGA	ATGCCCATGC 720
721	AGGATATCAA	GATGATCTTG	AAAAAGGTGC	AGCTGGAATC	TATTGAAGAT	TTGGAAGTGA 780
781	CTTGTACCTG	GAACTTACCC	ACCTTGGGGA	AAATTTCTCC	TTACCTGGGC	CAGATGATTA 840
841	ATCTGGGTAG	ACTCTCTCTC	TCCCACTATC	ATGCATCTTC	CTACATTTCG	CCGAGAGAGG 900
901	AAAGACAGTA	TATGGGCCAG	TTCACTCTTC	AGTTCTCTAG	TCTGCACTGC	CTGCAAGCTC 960
961	TCTATGTGGA	CTCTTATTTT	TTCTTGAAGG	GGCGCTGGA	TCAGTTCTTC	AGGCACGTGA 1020
1021	TGAACCCCTT	GGAAACCTTC	TCAATAACTA	ACTGCGGGCT	TTGGGAAGGG	GATGTGATGC 1080
1081	ATCTGTCCCA	GAGTCCCAAC	GTCACTCAGC	TAAGTGTCTT	GAGTCTAAGT	GGGCTCATGC 1140
1141	TGACCGATGT	AAGTCCCAAG	GGCCTCCAGG	CTCTGCTGGA	GAGAGCCTCT	GGCAACCTGC 1200
1201	AGGACCTGCT	CTTTGATGAG	TGTGGGATCA	CGATGATCA	GCTCCTTGGC	CTCCTGCTTT 1260
1261	CCCTGAGCCA	CTGCTCCAGG	CTTACAACTT	TAACTTTCTA	GGGGAATTCG	ATCTCCATAT 1320
1321	CTGCTTGGCA	GAGTCTCTCG	CAGCACTCTA	TGGGCTGAG	CAATCTGACC	CAGCTCTGCT 1380
1381	ATCTGTGCCC	CCTGGAGAGT	TATGAGGACA	TCCATGGTAC	CCTCCACCTG	GAGAGGCTTG 1440
1441	CCATATCTCA	TGCCAGGCTC	AGGAGATTTC	TGTGTGAGTT	GGGCGGCGCC	AGCATGCTCT 1500
1501	GGCTTAGTGC	CAACCCCTGT	CCTCACTGTG	GGGACAGAAC	CTTCTATGAC	CCGG 1554
	10	20	30	40	50	60

(SEQ ID NO. 1)

101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000

SEW ID NO. 2

We claim:

1. An isolated nucleic acid molecule consisting essentially of the nucleotide sequence set forth in SEQ ID NO: 1.
2. An isolated nucleic acid molecule consisting essentially of the nucleotide sequence set forth in SEQ ID NO : 2.
3. An isolated nucleic acid molecule which hybridizes, under stringent conditions, to the nucleic acid molecule set forth in SEQ ID NO: 1 or SEQ ID NO : 2, and codes for a tumor rejection antigen precursor, with the proviso that said isolated nucleic acid molecule does not code for any of a MAGE tumor rejection antigen precursor or a BAGE tumor rejection antigen precursor or a GAGE tumor rejection antigen precursor.
4. An isolated nucleic acid molecule consisting of nucleotides 1-1554 of SEQ ID NO: 1.
5. An isolated mRNA molecule which is complementary to the nucleic acid molecule of claim 1.
6. A host cell transfected or transformed with the nucleic acid molecule of claim 1.

7. A host cell transfected or transformed with the nucleic acid molecule of claim 3.
8. A host cell transfected or transformed with the nucleic acid molecule of claim 4.
9. An expression vector comprising the isolated nucleic acid molecule of claim 1 or claim 2, operably linked to a promoter.
10. An expression vector comprising the isolated nucleic acid molecule of claim 3 operably linked to a promoter.
11. An expression vector comprising the isolated nucleic acid molecule of claim 4, operably linked to a promoter.
12. The host cell of claim 6, wherein said host cell is a mammalian cell which expresses HLA-A24.
13. The host cell of claim 7, wherein said host cell is a mammalian cell which expresses HLA-A24.
14. The host cell of claim 8, wherein said host cell is a mammalian cell which expresses HLA-A24.
15. The expression vector of claim 9, further comprising a nucleic acid molecule which codes for HLA-A24.

16. The expression vector of claim 10, further comprising a nucleic acid molecule which codes for HLA-A24.
17. The expression vector of claim 11, further comprising a nucleic acid molecule which codes for HLA-A24.
18. Expression kit comprising a separate portion of each of:
 - (i) the isolated nucleic acid molecule of claim 1 or claim 2, and
 - (ii) a nucleic acid molecule which codes for HLA-A24.
19. Expression kit comprising a separate portion of each of:
 - (i) the isolated nucleic acid molecule of claim 3, and;
 - (ii) a nucleic acid molecule which codes for HLA-A24.
20. Expression kit comprising a separate portion of each of:
 - (i) the isolated nucleic acid molecule of claim 4, and;
 - (ii) a nucleic acid molecule which codes for HLA-A24.
21. An isolated tumor rejection antigen precursor coded for by the nucleic acid molecule of claim 1, 2, 3 or 4.
22. Isolated peptide of SEQ ID NO : 5 or SEQ ID NO : 7.




Figure 1

Figure 1A

Figure 1B

Figure 1C

2/5

FIG. 2A**FIG. 2B****FIG. 3**

Stimulator Cells	TNF Released by CTL 269/17 (pg/ml)			
	10	20	30	40
LB33-MEL.B-1				
COS				
COS + A24				
COS + A24 + cDNA 5E10				





Fig. 4





Fig. 5

5/5

FIG. 6

INTERNATIONAL SEARCH REPORT

International application N .
PCT/US95/12117**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) r to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.5; 435/240.2, 252.3, 254.11, 320.1; 530/300, 350, 395, 828

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE, BIOSIS, EMBASE, DERWENT WPI, APS, CHEM ABS, search terms: author names, dage, tumor, tumour, hla-a24, antigen, hi2, 5e10, cancer, cDNA, myeloma, trap, testis, ovary, endometrium

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim N .
A, P	US, A, 5,405,940 (BOON ET AL.) 11 April 1995, see entire document.	1-22

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

13 NOVEMBER 1995

Date of mailing of the international search report

06 DEC 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

RON SCHWADRON

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*